SG11202109575UA - Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases - Google Patents
Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseasesInfo
- Publication number
- SG11202109575UA SG11202109575UA SG11202109575UA SG11202109575UA SG11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- treatment
- fused ring
- induced diseases
- pyrimidone derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19162954 | 2019-03-14 | ||
| PCT/EP2020/056884 WO2020182990A1 (en) | 2019-03-14 | 2020-03-13 | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109575UA true SG11202109575UA (en) | 2021-09-29 |
Family
ID=65817822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109575UA SG11202109575UA (en) | 2019-03-14 | 2020-03-13 | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20230091047A1 (zh) |
| EP (1) | EP3938362A1 (zh) |
| JP (1) | JP2022524456A (zh) |
| KR (1) | KR20210139319A (zh) |
| CN (1) | CN113710667A (zh) |
| AR (1) | AR118358A1 (zh) |
| AU (1) | AU2020235270A1 (zh) |
| BR (1) | BR112021017415A2 (zh) |
| CA (1) | CA3132531A1 (zh) |
| CL (1) | CL2021002390A1 (zh) |
| CO (1) | CO2021011295A2 (zh) |
| CR (1) | CR20210482A (zh) |
| DO (1) | DOP2021000185A (zh) |
| EA (1) | EA202192512A1 (zh) |
| EC (1) | ECSP21067189A (zh) |
| IL (1) | IL286210A (zh) |
| JO (1) | JOP20210249A1 (zh) |
| MA (1) | MA55286A (zh) |
| MX (1) | MX2021011107A (zh) |
| PE (1) | PE20212325A1 (zh) |
| SG (1) | SG11202109575UA (zh) |
| TW (1) | TW202100524A (zh) |
| WO (1) | WO2020182990A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202227435A (zh) * | 2020-09-11 | 2022-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物 |
| WO2022087011A1 (en) * | 2020-10-21 | 2022-04-28 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2023205653A1 (en) * | 2022-04-20 | 2023-10-26 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2023205645A1 (en) * | 2022-04-20 | 2023-10-26 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| WO2024073559A1 (en) * | 2022-09-30 | 2024-04-04 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2078719A4 (en) * | 2006-09-28 | 2009-11-11 | Dainippon Sumitomo Pharma Co | COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION |
| CA2684633A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| CN101854597B (zh) | 2009-04-03 | 2015-06-03 | 中兴通讯股份有限公司 | 大消息模式融合ip消息传输方法及系统 |
| WO2011111880A1 (ko) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| JP2012126698A (ja) * | 2010-12-17 | 2012-07-05 | Tsutomu Takeuchi | テトラヒドロピリドピリミジン誘導体を有効成分とするｂａｆｆの結合阻害剤 |
| KR20170118706A (ko) * | 2014-12-30 | 2017-10-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염 감염을 치료하는 유도체 및 그 방법 |
| JP7019691B2 (ja) * | 2016-11-03 | 2022-02-15 | エフ．ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症の処置及び予防のための新規なテトラヒドロピリドピリミジン |
-
2020
- 2020-03-13 CN CN202080020919.0A patent/CN113710667A/zh active Pending
- 2020-03-13 AU AU2020235270A patent/AU2020235270A1/en not_active Abandoned
- 2020-03-13 CA CA3132531A patent/CA3132531A1/en active Pending
- 2020-03-13 MA MA055286A patent/MA55286A/fr unknown
- 2020-03-13 TW TW109108504A patent/TW202100524A/zh unknown
- 2020-03-13 BR BR112021017415A patent/BR112021017415A2/pt unknown
- 2020-03-13 US US17/438,767 patent/US20230091047A1/en active Pending
- 2020-03-13 PE PE2021001481A patent/PE20212325A1/es unknown
- 2020-03-13 MX MX2021011107A patent/MX2021011107A/es unknown
- 2020-03-13 EP EP20710938.0A patent/EP3938362A1/en active Pending
- 2020-03-13 AR ARP200100713A patent/AR118358A1/es unknown
- 2020-03-13 JP JP2021554985A patent/JP2022524456A/ja not_active Withdrawn
- 2020-03-13 JO JOP/2021/0249A patent/JOP20210249A1/ar unknown
- 2020-03-13 SG SG11202109575UA patent/SG11202109575UA/en unknown
- 2020-03-13 EA EA202192512A patent/EA202192512A1/ru unknown
- 2020-03-13 CR CR20210482A patent/CR20210482A/es unknown
- 2020-03-13 KR KR1020217032292A patent/KR20210139319A/ko unknown
- 2020-03-13 WO PCT/EP2020/056884 patent/WO2020182990A1/en active Application Filing
-
2021
- 2021-08-26 CO CONC2021/0011295A patent/CO2021011295A2/es unknown
- 2021-09-09 IL IL286210A patent/IL286210A/en unknown
- 2021-09-09 DO DO2021000185A patent/DOP2021000185A/es unknown
- 2021-09-10 EC ECSENADI202167189A patent/ECSP21067189A/es unknown
- 2021-09-13 CL CL2021002390A patent/CL2021002390A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113710667A (zh) | 2021-11-26 |
| JP2022524456A (ja) | 2022-05-02 |
| CA3132531A1 (en) | 2020-09-17 |
| WO2020182990A1 (en) | 2020-09-17 |
| MA55286A (fr) | 2022-01-19 |
| AR118358A1 (es) | 2021-09-29 |
| US20230091047A1 (en) | 2023-03-23 |
| CL2021002390A1 (es) | 2022-04-22 |
| KR20210139319A (ko) | 2021-11-22 |
| DOP2021000185A (es) | 2022-01-16 |
| TW202100524A (zh) | 2021-01-01 |
| EP3938362A1 (en) | 2022-01-19 |
| BR112021017415A2 (pt) | 2022-02-01 |
| IL286210A (en) | 2021-10-31 |
| PE20212325A1 (es) | 2021-12-14 |
| CO2021011295A2 (es) | 2021-09-20 |
| CR20210482A (es) | 2021-11-09 |
| JOP20210249A1 (ar) | 2023-01-30 |
| AU2020235270A1 (en) | 2021-08-12 |
| MX2021011107A (es) | 2022-01-19 |
| ECSP21067189A (es) | 2021-11-18 |
| EA202192512A1 (ru) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286210A (en) | Compressed ring pyrimidine history for use in the treatment of hbv infection or diseases caused by hbv | |
| IL276333B (en) | Cyclic sulfamoylarylamide history and their use as drugs to treat hepatitis b | |
| IL251285B (en) | 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of virus infection | |
| IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
| PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| EP3774775C0 (en) | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNO DEFICIENCY VIRUS REPLICATION | |
| IL276813B1 (en) | History of 4-substituted 5-amino-octahydrocyclopenta[c]pyrrole-5-carboxylic acid, their pharmaceutical combinations and their use in the treatment of diseases | |
| MX365114B (es) | Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades. | |
| JOP20210313A1 (ar) | مشتقات حلقية غير متجانسة مندمجة | |
| IL284125A (en) | History of quinoline for use in the treatment of inflammatory diseases | |
| EP3471738A4 (en) | PHOSPHATE-SUBSTITUTED CYCLIC NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | |
| EP3814326A4 (en) | DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE | |
| EP3790866A4 (en) | DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE | |
| EP4003355A4 (en) | DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE | |
| EP4003997A4 (en) | DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES | |
| MX2021014576A (es) | Derivados heterociclicos condensados como agentes antivirales. | |
| EP3500578A4 (en) | HETEROCYCLE SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | |
| EP3500579A4 (en) | CHROMAN-SUBSTITUTED TETRACYCLIC COMPOUNDS AND USES THEREOF FOR TREATING VIRUS DISEASES | |
| EP4003987A4 (en) | DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES | |
| MX2021014581A (es) | Derivados heterociclicos condensados. | |
| EP4083044A4 (en) | USE OF TRIAZOLOTRIAZINE DERIVATIVES TO TREAT DISEASES | |
| EP3768681A4 (en) | INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| EP3393585A4 (en) | SILANOUS HETEROCYCLIC COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES |